MaaT Pharma Presents Updated Positive Data in Early Access Program for Xervyteg® at the EHA Congress

MaaT Press release 13 June 2025

MaaT will present updated data for Xervyteg® (MaaT013) in treating acute Graft-versus-Host Disease (aGvHD) under the Early Access Program (EAP) at the European Hematology Association (EHA) Annual Congress 2025. This independent EAP dataset further supports the efficacy and safety profile of Xervyteg® previously shown in the pivotal ARES trial.  It also confirms the breakthrough potential of Xervyteg for aGvHD patients with limited treatment options, and serves as supportive data within the Marketing Authorisation Application (MAA) recently submitted to the European Medicines Agency (EMA).

Link to article : https://www.maatpharma.com/june-13-2025-maat-pharma-presents-updated-positive-data-in-early-access-program-for-xervyteg-at-the-eha-congress-validating-high-efficacy-observed-in-pivotal-ares-study-in-acute-graft-versus-h/